secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001193125-23-254189
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EMA grants orphan drug designation to ANX005 for GBS; Phase 3 enrollment complete
--------------------------------------------------------------------------------

- European Medicines Agency granted orphan drug designation to ANX005 for Guillain-Barré Syndrome.
- Target enrollment of 225 patients achieved in Phase 3 pivotal study of ANX005 in GBS.
- Company on track to report topline Phase 3 data in first half of 2024.
- EMA stated preliminary data show 'clinically relevant advantage' over intravenous immunoglobulin.
- Orphan designation includes 10 years of EU market exclusivity and reduced regulatory fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523254189/0001193125-23-254189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523254189/d568195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-254189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer